drugset / Trial / NCT00379509
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
Phase 1
Completed
20 enrolled
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving lapatinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib when given together with radiation therapy in treating patients with locally recurrent or chemotherapy-refractory locally advanced or metastatic breast cancer.
Timeline
- Start
- 2006-04
- Primary completion
- 2010-06
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lapatinib ditosylate | Small molecule | 500 mg | Oral |
| Subject | lapatinib ditosylate | Small molecule | 750 mg | Oral |
| Subject | lapatinib ditosylate | Small molecule | 1000 mg | Oral |
| Subject | lapatinib ditosylate | Small molecule | 1250 mg | Oral |
| Subject | lapatinib ditosylate | Small molecule | 1500 mg | Oral |